Norgine BV, of Amsterdam, the Netherlands, and Innovacell Biotechnologie AG, of Innsbruck, Austria, said they entered an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15, a personalized cell-based product concept based upon proliferating autologous myoblasts from a biopsy taken from the patients’ own muscle.